• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Aptevo Therapeutics Inc.

    8/14/25 6:59:56 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APVO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Aptevo Therapeutics Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    03835L504

    (CUSIP Number)


    08/14/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03835L504


    1Names of Reporting Persons

    L1 Capital Global Opportunities Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    164,300.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    164,300.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    164,300.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aptevo Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    2401 4th Avenue, Suite 1050, Seattle, WA 98121
    Item 2. 
    (a)Name of person filing:

    L1 Capital Global Opportunities Master Fund, Ltd.
    (b)Address or principal business office or, if none, residence:

    161A Shedden Road, 1 Artillery Court, PO Box 10085 Grand Cayman, Cayman Islands KY1-1001
    (c)Citizenship:

    Cayman Islands
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    03835L504
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    164,300 This amendment refers to a Schedule 13G filed with the Securities and Exchange Commission on June 23, 2025, covering 285,000 shares of Common Stock underlying Warrants purchased on June 18, 2025. The amounts in Row (5), (7) and (9) represent 164,300 Warrants, which are subject to a 4.99% beneficial ownership limitation. The amounts do not include an additional 1,345,075 Warrants, which are subject to a 4.99% beneficial ownership limitation. The percentage set forth on Row (11) of the cover page for the reporting person is based on 3,287,918 Common Stock outstanding as of August 11, 2025, based on the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025. David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer's securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.
    (b)Percent of class:

    4.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    164,300

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    164,300

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    L1 Capital Global Opportunities Master Fund, Ltd.
     
    Signature:/s/ David Feldman
    Name/Title:David Feldman, Director
    Date:08/14/2025
    Get the next $APVO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

    Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today.DetailsSession Title: Bi and Multispecific BiologicsTalk Title: Modular Multispecific

    1/15/25 8:00:00 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

    SEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common s

    12/12/24 12:50:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

    Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing mipletamig trialCohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual d

    12/12/24 9:00:00 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Aptevo Therapeutics with a new price target

    Roth Capital reiterated coverage of Aptevo Therapeutics with a rating of Buy and set a new price target of $50.00 from $64.00 previously

    5/28/21 8:33:45 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Aptevo Therapeutics Inc.

    SCHEDULE 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

    8/14/25 6:59:56 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Aptevo Therapeutics Inc.

    SCHEDULE 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

    8/14/25 2:00:27 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Aptevo Therapeutics Inc.

    10-Q - Aptevo Therapeutics Inc. (0001671584) (Filer)

    8/11/25 8:12:36 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Abdun-Nabi Daniel

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    8/8/25 4:36:41 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, CFO Taylor Daphne

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    8/8/25 4:35:41 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Grant Grady Iii

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    8/8/25 4:34:57 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aptevo Therapeutics Inc.

    SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

    11/14/24 3:45:38 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aptevo Therapeutics Inc.

    SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

    11/8/24 2:57:35 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aptevo Therapeutics Inc.

    SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

    2/14/24 3:24:02 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Leadership Updates

    Live Leadership Updates

    View All

    BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

    NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

    11/2/21 9:00:00 AM ET
    $AMGN
    $APVO
    $BCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations